Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the Nomination Committee’s proposal for a new Board of Directors that will be submitted to the 2017 Annual General Meeting. The 2016-2017 Nomination Committee comprises representatives of the company’s three largest shareholders at the end of the third quarter of 2016 who have accepted a seat on the Nomination Committee, and the Chairman of the Board. The composition of the 2016-2017 Nomination Committee was as follows:
- Anders Hallberg, Chairman of the Nomination Committee, representing HealthInvest Partners AB
- Maria Rengefors, representing Nordea Fonder
- Bo Öberg, representing the class A shareholders
- Anna Malm Bernsten, Chairman of the Board of Medivir
The Nomination Committee has agreed, ahead of the upcoming 2017 Annual General Meeting, to propose that a new Board of Directors be appointed by means of the re-election of the Board’s existing Members, namely Anders Ekblom, Anders R Hallberg, Helena Levander and Anna Malm Bernsten, and the new election of two Members, namely Bengt Julander and Bengt Westermark. The Committee also proposes the re-election of Anna Malm Bernsten as Chairman of the Board.
Thomas Axelsson and Johan Harmenberg have declined re-election.
Bengt Julander, born 1953. Bengt Julander is a pharmacist and has worked in the pharmaceutical sector since 1978. Since 1990, he has primarily acted as an investor in and Member of the Boards of pharmaceutical development companies. Bengt has extensive experience of developing and commercialising products. Bengt Julander is the CEO of Linc AB, which invests in life sciences, and a Member of the Boards of Bringwell AB, Linc AB, Livland Skog AB, Pharmalink AB, Proequo AB, Sedana Medical AB, Stille AB and Swevet AB, and of a number of smaller companies.
Bengt Westermark, born 1945. Bengt Westermark has been a Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986. Between 1996 and 2002, he was the Dean of the Faculty of Medicine at Uppsala University, and was also the Vice-Rector of Medicine and Pharmacy there from 1999 to 2002. From 2003 to 2013, he was the Chairman of the Swedish Cancer Society’s research council. He has published over 300 papers in scientific journals, primarily on the mechanisms for the uncontrolled growth of cancer cells. Bengt Westermark is a member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences. He is a Member of the Board of Hamlet Pharma AB and is also a member of various advisory groups for the financing of medical research. Bengt has received a number of prizes and awards for his research and has been cited over 25,000 times by other researchers.
For more information please contact:
Anders M Hallberg, HealthInvest Partners AB, +46 (0)8-440 38 30.
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.